ABOS — Acumen Pharmaceuticals, Inc. catalysts
Next verified catalyst
2026-10-01 — A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Ear · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10 (month) in 3mo
ESTIMATED |
READOUT
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participant
Phase 2 · Alzheimer Disease |
ABOS Acumen Pharmaceuticals, Inc. | sabirnetug |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|